Hourly refreshWed, Jul 15, 2026

Press Release Database

Recent press releases, indexed by topic.
Featured · Jul 15

Modular Medical Receives Research Demonstrating Positive Payor Reception ...

(PR-inside.com) Completed Independent Study Strongly Supports Favorable Payor Receptivity to Pivot's Differentiated Design and Simplified User Experience, and provides further validation of significant progress towards goal of achieving broad market access for Pivot SAN DIEGO, CA / ACCESS Newswire / July 15, 2026 / Modular Medical, Inc. ("Modular Medical" or "the Company") (NASDAQ:MODD), a commercial-stage medical device company that is commercializing the next generation of insulin delivery technology, today released findings from an independent market research study demonstrating positive receptivity to its FDA-cleared Pivot™ tubeless patch pump due to its differentiated design, streamlined user experience, and potential for reimbursement through the pharmacy ..

Finance · 12:00 UTC
AllFinanceCryptoAISaaSHealthcareReal EstateEnergyRetailAutomotiveGamingMediaEducation
In the wireUpdated hourly
Finance · Healthcare

Modular Medical Receives Research Demonstrating Positive Payor Reception ...

(PR-inside.com) Completed Independent Study Strongly Supports Favorable Payor Receptivity to Pivot's Differentiated Design and Simplified User Experience, and provides further validation of significant progress towards goal of achieving broad market access for Pivot SAN DIEGO, CA / ACCESS Newswire / July 15, 2026 / Modular Medical, Inc. ("Modular Medical" or "the Company") (NASDAQ:MODD), a commercial-stage medical device company that is commercializing the next generation of insulin delivery technology, today released findings from an independent market research study demonstrating positive receptivity to its FDA-cleared Pivot™ tubeless patch pump due to its differentiated design, streamlined user experience, and potential for reimbursement through the pharmacy ..

Jul 15 · 12:00PR-Inside
In the wire

How the IRS Decides Who Qualifies to Settle for Less - Clear Start ...

(PR-inside.com) The IRS approves only a fraction of Offer in Compromise applications each year, and understanding the math behind the decision is the difference between an accepted offer and a wasted filing. IRVINE, CA / ACCESS Newswire / July 15, 2026 / The Offer in Compromise (OIC) program lets qualifying taxpayers resolve a federal tax debt for less than the full balance - but it is also one of the most misunderstood tools in the tax code. Clear Start Tax says many applicants are rejected not because they don't deserve relief, but because they misjudge how the IRS calculates what it believes ..

Jul 15 · 12:00PR-Inside
In the wire

ITWA@Vietnam 2026 Brings Global Smart Electronics Manufacturing, Advanced Materials and Automation Technologies to Hanoi

ITWA@Vietnam returns Aug 5–7, 2026 at VEC Hanoi, offering free entry for manufacturers. Highlights include industry forums, skills training, robot demos, full-chain exhibits and buyer matching for smarter, greener manufacturing. [PR.com]

Jul 15 · 12:00PR.com
Automotive

Eagle Cash For Cars Announces Enhanced Junk Car Removal in Calgary Services

Calgary, Canada, 2026-07-15 — /EPR Network/ — Eagle Cash For Cars proudly announces enhanced junk car removal in Calgary services. The improved service offers faster [read full press release...]

Jul 15 · 11:59Express Press Release
In the wire

Introducing FreshSure™, a Solid Ozone Technology That Could Change How the World Eats

Denver-based AgTech startup Onza Corp launches with an ambition to commercialize solid gases, starting with nature's most powerful natural antimicrobial: ozone DENVER, July 15, 2026 /PRNewswire/ -- Every year, 48 million Americans get sick from contaminated food. Globally, nearly 1 in 10...

Jul 15 · 11:58PR Newswire
Healthcare

InnoCare Announces Phase III Study Results of TYK2 Inhibitor Soficitinib Meet Primary Endpoint in Patients with Atomic Dermatitis

BEIJING, July 15, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that registrational phase III clinical study results of novel TYK2 (Tyrosine Kinase 2) inhibitor soficitinib (ICP-332) met the primary endpoint in patients with moderate-to-severe atopic dermatitis (AD).

Jul 15 · 11:54GlobeNewswire

Just in

← Prev1235570Next →
Browse the full archive →